Analysis of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma

Shihai Wu, PhD, Rencui Quan, PhD, Ling Han, PhD, Huaqing Zhang, PhD, Baozhu Zhang, MD, Gang Xu, MD, Xianming Li, MD

Abstract
The present study aimed to retrospectively analyze the survival outcomes and prognostic factors for patients with nasopharyngeal carcinoma (NPC) receiving intensity-modulated radiotherapy (IMRT).

Clinical data was collected from 691 patients with NPC receiving IMRT from January 2009 to August 2015. A survival analysis was performed and prognostic factors were analyzed using the Kaplan–Meier method, the Cox proportional hazards regression model, and the log-rank test.

The median follow-up time was 62.8 months. Sixty-three patients experienced relapse, 44 cases (70%) of which occurred within 3 years. Six cases (9.5%) remained in remission for over 5 years. Seventy-two patients developed metastasis, 63 cases (87.5%) of which occurred within 3 years and only 1 case occurred after 5 years (1.3%). Five-year disease special survival (DSS), progression free survival, locoregional recurrence free survival, and distant metastasis free survival were 86.5%, 82.5%, 90.7%, and 89.4%, respectively, in patients with NPC. Patients with stage III NPC with and without induction chemotherapy had 5-year DSS rates of 95.8% and 89.3%, respectively (P = .00). Patients with stage Ia NPC with and without induction chemotherapy had 5-year DSS rates of 73.1% and 68.9%, respectively (P = .04). The 5-year DSS rates of patients with stage III with or without concurrent chemotherapy were 92.8% and 85.5%, respectively (P = .04). The 5-year DSS rates of patients with stage I with or without concurrent chemotherapy were 72.7% and 53.0% (P = .02).

IMRT improves the survival rate of patients with NPC. Recurrence and metastasis mainly occur within 2 to 3 years after radiotherapy. Induction and concurrent chemotherapy improve the 5-year DSS of patients with locally advanced NPC.

Abbreviations: CCRT = concurrent chemoradiotherapy, DMFS = distant metastasis free survival, DSS = disease-special survival, IC = induction chemotherapy, IMRT = intensity-modulated radiotherapy, LRFS = locoregional recurrence free survival, NPC = nasopharyngeal carcinoma, OS = overall survival, PFS = progression free survival.

Keywords: concurrent chemotherapy, intensity-modulated radiotherapy, nasopharyngeal carcinoma, survival analysis

1. Introduction

Nasopharyngeal carcinoma (NPC) has a distinct geographical distribution. Guangdong is one of the remarkable endemic areas with an annual morbidity of 30 to 40/100,000 compared with 0.5 to 1/100,000 in America.[1,2] There are 3 main subtypes of NPC: keratinizing squamous cell NPC, non-keratinizing squamous cell NPC, and basaloid squamous cell NPC according to the World Health Organization. The non-keratinizing squamous cell NPC is the dominating pathological subtype associated with Epstein–Barr virus infection among the endemic areas of south and east Asia, which can be divided into differentiated and undifferentiated tumors that are sensitive to radiation.[3,4] Radiotherapy is the mainstay therapy for non-metastatic disease and has advanced from conventional 2-dimensional or 3-dimensional radiotherapy to intensity-modulated radiotherapy (IMRT). In the last 20 years, IMRT has allowed an increase in the dose of radiation applied to tumor lesions, while reducing radiotherapy-related toxicity to surrounding organs. Previous studies have shown that IMRT reduced the 5-year LRFS compared with conventional techniques.[5–7] and patients with NPC receiving IMRT had a 5-year overall survival (OS) of 75% to 83%, a DSS of 79% to 85%, a LRFS of 90% to 95%, and DMFS of 85% to 90%.

Treatments for NPC are based on the stage of the disease. While patients with stage I and II NPC usually receive concurrent chemoradiotherapy (CCRT), patients with stage III and IVa NPC
undergo induction chemotherapy (IC) or adjuvant chemotherapy combined with CCRT. A number of randomized trials have demonstrated the survival benefit of CCRT with IC or adjuvant chemotherapy in patients with NPC, and survival benefits have been proved through indirect comparison between them. Compared with adjuvant chemotherapy, IC has evident advantages in producing better tolerance and earlier eradication of micro-metastases.\cite{8–15} The related adverse events, especially hematologic toxicity and radiation-induced oral mucositis, may require extra attention. Meanwhile, it is reported that anti-epidermal growth factor receptor (EGFR) agents, such as cetuximab and nimotuzumab, when used in combination with IC or CCRT, improve of progression-free survival (PFS), DMFS, and OS.\cite{13–15}

High programmed cell death ligand-1 (PD-L1) expression is observed in up to 90% of tumor cell in NPC.\cite{13} Recently, immune checkpoint blockade therapy has undergone breakthroughs in NPC immunotherapy as objective response ranging from 20% to 30%, 1-year OS ranging from 59% to 63%, 1-year PFS ranging from 19% to 33% after monotherapy were reported.\cite{16} In combination trials, the objective response can increase to 91% and 1-year PFS can increase to 61%.\cite{17} The immunotherapy is mainly focused on recurrence and metastasis of NPC and there is a little data about immunotherapy combined with radiotherapy for the treatment of NPC. But there are some phase 2 or 3 randomized clinical trials about immunotherapy combined with concurrent chemo-radiotherapy for high-risk NPC undergoing in Sun Yat-Sen University Cancer Center (NCT03984357, NCT03925090, NCT03427827, NCT03700476).

This study retrospectively analyzed clinical data from 691 patients with NPC receiving IMRT at Shenzhen People’s Hospital and explored the failure patterns with the aim of providing a pivotal prognostic reference for future clinical research.

2. Methods

2.1. Patients and data collection

This is a retrospective study and the ethical approval was not necessary. A total of 691 newly diagnosed patients with non-metastatic NPC at Shenzhen People's Hospital between January 2009 and June 2015 were enrolled. The inclusion criteria were as follows:

(1) patients with NPC and nasopharyngeal mass biopsies that were histologically classified as keratinized or non-keratinized and imaging-confirmed absence of distant metastasis;

(2) absence of other concurrent malignant tumors;

(3) patients receiving IMRT treatment. The 6th-edition classification from the Union for International Cancer Control was used for diagnosis.

2.2. Treatments

The target volume delineation for patients receiving IMRT was determined using guidelines 50 and 62 of the International Commission on Radiation Units. The prescribed dose was 68 to 70 Gy to the gross target volume of the nasopharynx, 64 to 68 Gy to cervical lymph node metastasis, 60 Gy to high-risk clinical target volume, and 54 Gy to low-risk clinical target volume, each with 33 fractions. For patients receiving induction or adjuvant chemotherapy, these regimens were administered every 21 days and a total of 2 to 3 cycles were applied prior or posterior to radiotherapy. The regimens were as follows:

(1) cisplatin, fluorouracil, and docetaxel (TPF) regimen, 60 mg/m²/d paclitaxel and cisplatin and 600 mg/m²/d1 to 5 fluorouracil;

(2) cisplatin and fluorouracil (PF) regimen, 80 mg/m²/d cisplatin and 800 mg/m²/d1 to 5 fluorouracil;

(3) cisplatin and docetaxel (TP) regimen, 80 mg/m²/d1 paclitaxel and cisplatin. Cisplatin as a single agent was administered on days 2 and 23 during radiotherapy for concurrent chemotherapy, whereas nimotuzumab was administered to patients with stage III to IVa NPC for targeted therapy at a dose of 200 mg once per week.

2.3. Follow up and evaluation criteria

Patients were asked to return to our clinic every 3 months for nasopharyngeal and neck magnetic resonance imaging in the first 2 years. This follow up was gradually decreased to every 6 months in the following 3 years and to once annually for patients without observed relapse or metastasis. Patients received at least 1 comprehensive check annually including nasal endoscopy, chest-abdomen computed tomography, and an emission computed tomography bone scan or whole-body positron emission tomography. Several endpoints were used in this study. The definition of endpoint OS was the time from diagnosis to death of any cause, and loss to follow up was marked as censored data. DSS was defined as the time from diagnosis to death from NPC, and loss to follow up or death from other causes were marked as censored data. In addition, PFS was defined as the time from diagnosis to locoregional or distant failure, while LRFS was defined as the time from diagnosis to locoregional failure. DMFS was defined as the time from diagnosis to distant failure, and loss to follow up or death from any cause was marked as censored data.

2.4. Statistical analysis

Survival curves were created using the Kaplan–Meier method and compared with the help of the log-rank test. Cox multivariate regression modeling was used to evaluate the prognostic factors. SPSS 22.0 software (IBM.com) was used for statistical analysis where P < .05 was considered statistically significant.

3. Results

3.1. Demographic and pathological features

A total of 509 males and 182 females were enrolled in the study with a median age of 44 years (15–80 years) and a male to female ratio of 2.8 (Table 1). Twenty-seven (3.9%) patients were identified as stage I, and 118 (17.1%), 343 (49.6%), and 203 (29.4%) patients were identified as stage II, III, and IVa, respectively. Of the 691 patients receiving IMRT, 238 (34.4%) and 458 (66.3%) patients received induction and concurrent chemotherapy, respectively, while 73 (10.6%) and 137 (19.8%) patients received adjuvant chemotherapy and targeted therapy, respectively.

3.2. Survival

The follow up ended on June 30th, 2018 with a median of 62.8 months. Sixty-three patients experienced relapse, of which
44 (69.8%) presented with nasopharyngeal recurrence, 17 (27.0%) presented with locoregional lymph node recurrence, and 2 (3.2%) presented with combined recurrence (Table 1). Recurrence was observed 4 to 91 months after radiotherapy with 70% of patients experiencing relapse within 3 years, 30% of patients experiencing relapse beyond 3 years, and 9.5% of patients remaining in remission for 5 years before experiencing relapse.

Of the 72 patients with distant metastases, 34 (47.2%), 14 (16.7%), and 12 patients had multiple metastases, liver metastasis, and lung and bone metastases, respectively. It is worth highlighting that 10 patients experienced distant metastasis and relapse simultaneously. Distant metastasis was observed 3 to 66 months after radiotherapy; 87.5% of distant metastases occurred in the first 3 years and 12.5% of distant metastases occurred beyond 3 years. Only 1.3% of patients experienced distant failure after 5 years (data not shown).

To better understand the survival and prognostic patterns of patients with NPC, we performed a survival analysis based on different study endpoints. For all patients in the study, 5-year OS, DSS, PFS, LRFS, and DMFS were 85.8%, 86.5%, 82.5%, 90.7%, and 89.4%, respectively. Patients with stage I NPC exhibited an OS as high as 95.8%, and 100% DSS, PFS, LRFS, and DMFS. Patients with stage II and III NPC showed lower but comparable survival rates at each endpoint (OS: 96.5% vs 91.1%; DSS: 96.5% vs 91.4%; PFS: 95.9% vs 87.0%; LRFS: 99.2% vs 93.5%; DMFS: 96.0% vs 92.7%, respectively). As anticipated, patients with stage IV NPC had relatively low OS (69.7%), DSS (69.7%), PFS (64.8%), LRFS (83.4%), and DMFS (76.1%) rates (Table 2 vs Fig. 1-ABCD).

### 3.3. Prognostic factor analysis

To assess the factors influencing the prognosis of patients with NPC, a backward selection in the Cox regression model was used, and gender, age, T stage, N stage, and type of chemotherapy were the variables. We showed that gender, T stage, and N stage independently affected DSS, PFS, LRFS, and DMFS. In addition, patients receiving CCRT had significantly higher OS, DSS, and LRFS rates (Table 3).

### 3.4. The effect of chemotherapy on the efficacy of treatment of regional advanced NPC

To examine whether different chemotherapy regimens influence disease onset, we compared 5-year DSS in patients with stage III and IVa NPC receiving IC, CCRT, and targeted therapy. While targeted therapy exerted no effect on patient prognosis, IC and CCRT significantly improved the DSS of patients with stage III and IVa NPC, indicating better treatment options for patients with regional advanced NPC (Table 4). Our data also showed an overall poor prognosis for patients with stage IVa NPC with a DSS of <73.1%, despite the chemotherapy regimen being administered.

### 3.5. Second primary malignancy and distant severe complications

We observed a second primary malignancy in 17 patients during the follow-up period with a median development time of 60 months (36–83 months). Four of the 17 patients developed lung cancer and 2 patients developed each of liver cancer, gastric carcinoma, and glioma. The remaining 7 patients developed osteosarcoma of the maxilla (n = 1), esophageal cancer (n = 1), gingival carcinoma (n = 1), tongue cancer (n = 1), laryngeal cancer (n = 1), colon cancer (n = 1), or bladder cancer (n = 1); data not

---

### Table 1

**Characteristics of 691 patients with nasopharyngeal carcinoma.**

| Characteristics     | Number | %    |
|---------------------|--------|------|
| Gender              |        |      |
| Male                | 509    | 73.7 |
| Female              | 182    | 26.3 |
| Age                 |        |      |
| < 50 yr             | 447    | 64.7 |
| ≥ 50 yr             | 244    | 35.3 |
| T stage             |        |      |
| T1                  | 132    | 19.1 |
| T2                  | 237    | 34.3 |
| T3                  | 200    | 30.2 |
| T4                  | 113    | 16.4 |
| N stage             |        |      |
| N0                  | 69     | 10.0 |
| N1                  | 169    | 24.5 |
| N2                  | 335    | 48.5 |
| N3                  | 118    | 17.1 |
| TNM stage           |        |      |
| I                   | 27     | 3.9  |
| II                  | 118    | 17.1 |
| III                 | 343    | 49.6 |
| IVa                 | 203    | 29.4 |
| Induction chemotherapy |     |      |
| Yes                 | 238    | 34.4 |
| No                  | 453    | 65.6 |
| Concurrent chemotherapy |     |      |
| Yes                 | 458    | 66.3 |
| No                  | 233    | 33.7 |
| Adjuvant chemotherapy |     |      |
| Yes                 | 73     | 10.6 |
| No                  | 618    | 89.4 |
| Targeted therapy    |        |      |
| Yes                 | 137    | 19.8 |
| No                  | 554    | 80.2 |
| Recurrence          |        |      |
| Yes                 | 63     | 9.1  |
| No                  | 628    | 90.9 |
| Metastasis          |        |      |
| No                  | 619    | 89.6 |
| Lung                | 12     | 1.7  |
| Liver               | 14     | 2.0  |
| Bone                | 12     | 1.7  |
| Multiple*           | 34     | 4.9  |

* Metastasis observed in 2 or more locations.

TNM = tumor-node-metastasis

### Table 2

**Treatment efficacy in patients with different stages of nasopharyngeal carcinoma.**

| Stage   | 5-yr OS | 5-yr DSS | 5-yr PFS | 5-yr LRFS | 5-yr DMFS |
|---------|---------|----------|----------|-----------|-----------|
| Overall | 85.8%   | 86.5%    | 82.5%    | 90.7%     | 89.4%     |
| I       | 95.8%   | 100%     | 100%     | 100%      | 100%      |
| II      | 96.5%   | 96.5%    | 95.9%    | 99.2%     | 96.0%     |
| III     | 91.4%   | 91.4%    | 87.0%    | 93.5%     | 92.7%     |
| IVa     | 69.7%   | 69.7%    | 64.8%    | 83.4%     | 76.1%     |

OS = overall survival, DSS = disease-specific survival, PFS = progression-free survival, LRFS = local recurrence-free survival, DMFS = distant metastasis-free survival.
shown). All patients died despite no recurrence or metastasis. In addition to the aforementioned 17 subjects, we also observed distant severe complications in 8 subjects. Four subjects experienced damage to the posterior cranial nerve, 2 patients had gross nasopharyngeal bleeding, and 2 patients experienced carotid artery rupture.

A total of 109 deaths occurred during the study. One hundred two subjects died from tumor or tumor-related complications and 7 died from non-tumor causes (2 from severe lung infection, 2 from cerebral infarction, 1 from myocardial infarction, 1 from depression, and 1 from femoral fracture).

4. Discussion

IMRT has replaced conventional radiation therapy and has been the main therapeutic technique for NPC since the beginning of the 21st century due to its distinct advantages on dose control and target delineation. IC and CCRT is significantly associated with better locoregional control and OS. Anti-EGFR agents in conjunction with CCRT are associated with significantly increased OS and DFS rates, as well as improved DMFS. With this approach, the main adverse events are mild skin reactions and mucositis. Recent progress in tumor immunotherapy make it a promising therapeutic approach for advanced NPC, but strong evidence for tumor immunotherapy in early NPC is lacking.

In this study, we further confirmed that IMRT can increase the survival of patients with NPC. We showed that the 5-year OS, DSS, PFS, LRFS, and DMFS rates were 85.8%, 86.5%, 82.5%, 90.7%, and 89.4%, respectively. We also showed that 5-year LRFS and DMFS rates in patients with stage I NPC were 100% and 100%, respectively; stage II NPC were 99.2% and 96.0%,
respectively, during the follow-up period, during which patients experienced relapse within 4 to 91 months and metastasis within 3 to 66 months of receiving radiation therapy. Although 70% of relapses occurred within 3 months and up to 9.5% of patients remained in remission for 5 years, 87% of metastases developed within 3 years and only 1.3% occurred after 5 years. Setton et al also showed that more than half of the observed local relapses occurred after 2 years. Our study demonstrated that patients with NPC typically experience recurrence and metastasis within 2 to 3 years of receiving radiotherapy, which is a common characteristic also reported in other studies. The failure pattern of NPC is distinct from that of carcinomas arising from other head and neck sites. These findings raise the possibility that patients with NPC may benefit from close follow-up during post-treatment years 3 to 5.

Our study suggests that, when combined with the tumor-node-metastasis classification, the T and N stages of NPC are precise prognostic factors, as no crossovers were observed in the survival curves from our multivariate analysis of prognosis. The incidences of recurrence and metastasis observed in this study were 73.0% and 22.2%, respectively, in patients with stage T3 and T4; and 65.0% and 47.2%, respectively, in patients with stage N3 (data not shown). Sun et al reported 5-year LRFS rates of 100.0%, 96.0%, 90.4%, and 83.3% in patients with stage T1, T2, T3, and T4 NPC, respectively, as well as 5-year DMFS rates of 96.1%, 85.6%, 73.7%, and 62.1% in patients with stage N0, N1, N2, and N3 NPC, respectively. In accordance with their findings, we found that the 5-year LRFS rates in patients with stage T1, T2, T3, and T4 disease were 98.3%, 96.0%, 90.5%, and 79.0%, respectively (P < .00). Furthermore, the 5-year DMFS rates in patients with stage N0, N1, N2, and N3 were 100%, 97.0%, 90.0%, and 70.9%, respectively (P = .00). The T and N stages are associated with LRFS and DMFS, respectively, in 177 consecutive newly diagnosed patients with non-metastatic NPC treated with definitive IMRT between 1998 and 2011. Meanwhile, we reported 63 and 72 cases of recurrence and metastasis, respectively; stage III NPC were 93.5% and 92.7%, respectively; and stage IVa NPC were 83.4% and 76.1%, respectively. These observations are in agreement with previous studies. Setton et al reported 3-5-year actuarial OS, LRFS, and DMFS rates of 87%/74%, 92%/83%, and 86%/83%, respectively, in 177 consecutive newly diagnosed patients with non-metastatic NPC treated with definitive IMRT between 1998 and 2011. Meanwhile, we reported 63 and 72 cases of recurrence and metastasis, respectively; stage III NPC were 93.5% and 92.7%, respectively; and stage IVa NPC were 83.4% and 76.1%, respectively. These observations are in agreement with previous studies. Setton et al reported 3-5-year actuarial OS, LRFS, and DMFS rates of 87%/74%, 92%/83%, and 86%/83%, respectively, in 177 consecutive newly diagnosed patients with non-metastatic NPC treated with definitive IMRT between 1998 and 2011.

### Table 3
Prognostic factors analysis.

| Endpoints | Variables | HR    | 95%CI | P    |
|-----------|-----------|-------|-------|------|
| OS        | Gender    | 2.03  | 1.21–3.42 | .00  |
|           | Age       | 1.84  | 1.25–2.70 | .00  |
|           | T stage   | 1.73  | 1.39–2.13 | .00  |
|           | N stage   | 2.09  | 1.61–2.72 | .00  |
|           | Concurrent chemotherapy | 0.62  | 0.40–0.95 | .02  |
| DSS       | Gender    | 2.41  | 1.37–4.25 | .00  |
|           | Age       | 1.77  | 1.19–2.63 | .00  |
|           | T stage   | 1.88  | 1.51–2.34 | .00  |
|           | N stage   | 2.20  | 1.66–2.89 | .00  |
|           | Concurrent chemotherapy | 0.61  | 0.39–0.95 | .03  |
| PFS       | Gender    | 1.88  | 1.18–3.02 | .00  |
|           | T stage   | 1.71  | 1.41–2.08 | .00  |
|           | N stage   | 2.09  | 1.64–2.65 | .00  |
| LRFS      | Gender    | 2.39  | 1.18–4.85 | .02  |
|           | T stage   | 2.22  | 1.66–2.95 | .00  |
|           | N stage   | 1.55  | 1.11–2.15 | .01  |
|           | Concurrent chemotherapy | 0.50  | 0.29–0.86 | .01  |
| DMFS      | Gender    | 2.27  | 1.16–4.42 | .02  |
|           | T stage   | 1.49  | 1.15–1.93 | .00  |
|           | N stage   | 3.22  | 2.26–4.57 | .00  |

Female patients, age less than 55 years with T1 and N0 nasopharyngeal carcinoma, without receiving concurrent chemotherapy were used as reference group.

OS = overall survival, DSS = disease-specific survival, PFS = progress-free survival, LRFS = local recurrence-free survival, DMFS = distant metastasis-free survival.

### Table 4
The effect of different chemotherapy on 5-years disease-specific survival in patients with regional advanced nasopharyngeal carcinoma.

| Stage | Treatment        | Number | 5-year DSS | P    |
|-------|------------------|--------|------------|------|
| III   | Induction chemotherapy |       |            |      |
|       | Yes              | 121    | 95.8%      | .00  |
|       | No               | 222    | 89.3%      |      |
|       | Concurrent chemotherapy |       |            |      |
|       | Yes              | 260    | 92.8%      | .04  |
|       | No               | 83     | 85.5%      | .04  |
|       | Targeted therapy |         |            |      |
|       | Yes              | 75     | 90.1%      | .29  |
|       | No               | 268    | 91.1%      |      |
| IVa   | Induction chemotherapy |       |            |      |
|       | Yes              | 112    | 73.1%      | .04  |
|       | No               | 91     | 68.9%      |      |
|       | Concurrent chemotherapy |       |            |      |
|       | Yes              | 172    | 72.7%      | .02  |
|       | No               | 31     | 53.0%      |      |
|       | Targeted therapy |         |            |      |
|       | Yes              | 40     | 63.7%      | .17  |
|       | No               | 154    | 71.6%      |      |

The comparison among groups were statistically significant, P < .05.

DSS = disease-specific survival.
5. Conclusion
We achieved a treatment efficacy that was comparable with other large national medical institutions with distant metastasis being the main cause of treatment failure in patients with NPC. The tumor-node-metastasis classification is related to survival. While combining IC and concurrent chemotherapy with IMRT can improve 5-year DSS, the impact of targeted therapy on patients with advanced NPC requires further investigation. Finally, close monitoring and early detection of second primary tumors is pivotal as patients’ survival times increase.

Author contributions
Conceptualization: Gang Xu, Xianming Li.
Data curation: Shihai Wu, Rencui Quan, Ling Han, Huaqing Zhang. Baoyu Zhang.
Formal analysis: Shihai Wu, Rencui Quan, Ling Han, Huaqing Zhang. Baozhu Zhang.
Methodology: Shihai Wu, Huaqing Zhang.
Supervision: Gang Xu, Xianming Li.
Writing – original draft: Shihai Wu, Rencui Quan.

References
[1] de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020;8:e180–90.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
[3] Chen YP, Chan A, Le QT, et al. Nasopharyngeal carcinoma. Lancet 2019;394:64–80.
[4] Pathmanathan R, Prasad U, Chandrika G, et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1993;143:1355–67.
[5] Du T, Xiao J, Qiu Z, et al. The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. Plos One 2019;14:e21961.
[6] Zhang B, Mo Z, Du W, et al. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. Oral Oncol 2015;51:1041–6.
[7] Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 2012;104:286–93.
[8] Li WF, Chen NY, Zhang N, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer 2019;145:295–305.
[9] Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res 2018;24:1824–33.
[10] Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer 2017;75:14–23.
[11] Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016;17:1309–20.
[12] Tang S, Xu C, Wang X, et al. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis. Oral Oncol 2020;105:104686.
[13] Zhi-Qiang W, Qi M, Ji-Bin L, et al. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without nimotuzumab: a propensity score-matched analysis. BMC Cancer 2019;19:1122.
[14] Lu Y, Chen D, Liang J, et al. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study. BMC Cancer 2019;19:1262.
[15] Ma B, Lim WT, Goh BC, et al. Antitumor activity of nimotuzumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo clinic phase 2 consortium (NCl-9742). J Clin Oncol 2018;36:1412–8.
[16] Hsu C, Lee SH, Ejidi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol 2017;35:4050–6.
[17] Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018;19:1338–50.
[18] Jiang F, Jin T, Feng XL, et al. Long-term outcomes and failure patterns of patients with nasopharyngeal carcinoma staged by magnetic resonance imaging in intensity-modulated radiotherapy era: the Zhejiang Cancer Hospital’s experience. J Cancer Res Ther 2015;11(Suppl 2):C179–84.
[19] Liang SB, Wang Y, Hu XF, et al. Survival and toxicities of IMRT based on the RTOG protocols in patients with nasopharyngeal carcinoma from the endemic regions of China. J Cancer 2017;8:3718–24.
[20] Tian YM, Lin MZ, Zeng L, et al. Long-term outcome and pattern of failure for patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Head Neck 2019;41:1246–52.
[21] Au KH, Ngan RKC, Ng AWY, et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong; a report of 3328 patients (HKNPCG 1301 study). Oral Oncol 2018;77:16–21.
[22] Chuang DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005;23:1118–24.
[23] Li Z, Li Y, Yan S, et al. Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma. Onco Targets Ther 2017;10:5445–58.
[24] Lin M, You R, Liu Y, et al. Beneficial effects of anti-EGFR agents, cetuximab or nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma. Oral Oncol 2018;80:1–8.
[25] You R, Hua Y, Liu Y, et al. Concurrent chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics 2017;7:2314–24.
[26] Setton J, Han J, Kamaranimit D, et al. Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma. Oral Oncol 2016;53:67–73.
[27] Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 2014;110:398–403.
[28] Xue F, Hu C, He X. Long-term patterns of regional failure for nasopharyngeal carcinoma following intensity-modulated radiotherapy. J Cancer 2017;8:993–9.